Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 9/11/2018
SIETES contiene 92577 citas

 
 
 1 a 20 de 544 siguiente >>
Presentar resultados
Seleccionar todas
4. Cita con resumen
Habibi R, Lexchin J, Mintzes B, Holbrook A. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. Br J Clin Pharmacol 2017;83:2549-56. [Ref.ID 102116]
6. Cita con resumen
Thomas K. Celgene to pay $280 Million to settle fraud suit over cancer drugs. N Y Times (Print) 2017:1. [Ref.ID 101924]
8.Enlace a cita original
Anónimo. Armodafinil for sleep disorders. Australian Prescriber 2016;39:221. [Ref.ID 101022]
10. Cita con resumen
DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin J. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med 2016;176:1114. [Ref.ID 100701]
11. Cita con resumen
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]
12. Cita con resumen
Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim S. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med 2016;176:junio. [Ref.ID 100237]
13. Cita con resumen
Robert L, Llop R, Juarez JC, Diego L. Mantenir-se al dia en farmacoterapèutica: el paper del web 2.0 i les xarxes socials.. Butlletí d'Informació Terapèutica 2016;27:9-16. [Ref.ID 100157]
14. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
15. Cita con resumen
Chinthapalli K. The billion dollar business of being smart. BMJ 2015;351:h4829. [Ref.ID 99542]
16. Cita con resumen
Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications - Loosening the rules. N Engl J Med 2015;373:967-73. [Ref.ID 99432]
17. Cita con resumen
Roehr B. Court rules that FDA cannot restrict off-label marketing. BMJ 2015;351:h4367. [Ref.ID 99403]
18. Cita con resumen
Ornstein C, Jones RG. Vying for market share, companies heavily promote ‘me too’ drugs. ProPublica 2015:7 de enero. [Ref.ID 98702]
19. Cita con resumen
Anónimo. Analysis: drug companies increasingly marketing to hospital administrators. DIA Daily 2014:25 de septiembre. [Ref.ID 97956]
20.Tiene citas relacionadas Cita con resumen
Steinbrook R. Should medical journal publish sponsored content?. BMJ 2014;348:g352. [Ref.ID 97341]
Seleccionar todas
 
 1 a 20 de 544 siguiente >>